April 01, 2022
In an OncView program, Roy Herbst, MD, PhD, touched on clinical decision-making, monitoring response, and the potential treatment options available for treating non–small cell lung cancer.
January 01, 2022
Roy S. Herbst, MD, PhD, discussed implementing immunotherapy and seeing its effectiveness in patients with lung cancer.
October 25, 2021
Roy S. Herbst, MD, PhD, shares insight on approaching clinical decision-making for the length of immunotherapy treatment and drug holidays for patients with NSCLC.
October 25, 2021
An expert in thoracic oncology provides an overview of ctDNA and discusses what ctDNA testing results can indicate about a patient’s likelihood of responding to immunotherapy in NSCLC.
October 18, 2021
Roy S. Herbst, MD, PhD, reviews indicators of relapse or progression of disease when monitoring patients on therapy in NSCLC.
October 18, 2021
Roy S. Herbst, MD, PhD, provides insight on selecting the optimal therapy for non–small-cell lung cancer and shares considerations for the use of combination chemotherapy and immunotherapy.
February 26, 2021
The KEYNOTE-010 study evaluated the use of either pembrolizumab or docetaxel in patients with previously treated, PD-L1–positive advanced non–small cell lung cancer.
June 15, 2020
Roy S. Herbst, MD, PhD, presented a late breaking abstract on behalf of his colleagues regarding the ADAURA trial, which analyzed osimertinib as an adjuvant therapy to treat patients with non-small cell lung cancer.
June 12, 2020
Roy S. Herbst, MD, PhD, of the Yale Cancer Center discussed the future of lung cancer treatment to follow the phase III ADAURA trial regarding osimertinib as adjuvant therapy to treat NSCLC presented at the 2020 ASCO Virtual Scientific Program.
June 03, 2020
Roy S. Herbst, MD, PhD, of the Yale Cancer Center discussed his key takeaway from the phase III ADAURA trial regarding osimertinib as adjuvant therapy to treat NSCLC presented at the 2020 ASCO Virtual Scientific Program.